{
    "2020-10-31": [
        [
            {
                "time": "2020-01-01",
                "original_text": "EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Incyte",
                        "Baricitinib",
                        "Atopic Dermatitis",
                        "New Data",
                        "Treatment"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "Point/Counterpoint: The Case for Eli Lilly",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Point/Counterpoint",
                        "Case"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}